Taylor Frigon Capital Management LLC Has $3.64 Million Stake in Glaukos Co. (NYSE:GKOS)

Taylor Frigon Capital Management LLC trimmed its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 29.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,022 shares of the medical instruments supplier's stock after selling 11,654 shares during the quarter. Glaukos makes up 1.8% of Taylor Frigon Capital Management LLC's investment portfolio, making the stock its 10th largest position. Taylor Frigon Capital Management LLC owned approximately 0.06% of Glaukos worth $3,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of GKOS. Caldwell Sutter Capital Inc. lifted its holdings in Glaukos by 5,860.0% in the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier's stock worth $140,000 after buying an additional 1,465 shares during the period. GAMMA Investing LLC lifted its holdings in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock worth $141,000 after buying an additional 486 shares during the period. Fifth Third Wealth Advisors LLC purchased a new stake in Glaukos in the 2nd quarter worth approximately $187,000. Brighton Jones LLC purchased a new stake in Glaukos in the 2nd quarter worth approximately $208,000. Finally, Procyon Advisors LLC purchased a new stake in Glaukos in the 3rd quarter worth approximately $210,000. 99.04% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares of the company's stock, valued at $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, COO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the sale, the chief operating officer now owns 102,169 shares of the company's stock, valued at $13,216,581.84. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company's stock, valued at $4,225,345.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,250 shares of company stock valued at $4,825,873. Corporate insiders own 6.40% of the company's stock.

Glaukos Stock Up 0.4 %

NYSE:GKOS traded up $0.53 during trading hours on Thursday, reaching $130.47. 368,257 shares of the company traded hands, compared to its average volume of 570,384. The business's 50-day moving average price is $128.90 and its two-hundred day moving average price is $117.87. The stock has a market capitalization of $6.57 billion, a P/E ratio of -45.57 and a beta of 1.02. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $136.60. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, hitting analysts' consensus estimates of ($0.52). The business had revenue of $95.70 million during the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The company's quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.55) EPS. Analysts predict that Glaukos Co. will post -2.18 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on GKOS. Wells Fargo & Company increased their price objective on Glaukos from $120.00 to $135.00 and gave the stock an "overweight" rating in a report on Thursday, August 1st. StockNews.com upgraded Glaukos from a "sell" rating to a "hold" rating in a research note on Monday. Morgan Stanley raised their target price on Glaukos from $100.00 to $120.00 and gave the company an "equal weight" rating in a research note on Monday, July 15th. Needham & Company LLC raised their target price on Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. Finally, Truist Financial raised their target price on Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $130.45.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.